Pharmaceutical Technology

JULY 29, 2022

The open-label, three-cohort, multicentre trial analysed intravesical BCG, N-803 combination in BCG-unresponsive high-grade NMIBC patients. This is a compelling example of the power of inducing trained innate immune memory to potentially provide long-term, durable effects against serious, life-threatening diseases.”.

Labelling 105

Labelling Immunity Immunization Vaccines 105

European Pharmaceutical Review

SEPTEMBER 22, 2022

The removal of HIV DNA from the cellular genome is essential to effecting a cure; the virus takes up long-term residence in tissue reservoirs, where it hides, evading the immune system and escaping antiretroviral therapy. As a result, HIV can persist in tissue reservoirs for years.

Labelling 145

Labelling Immunity Immunization 145

pharmaphorum

AUGUST 4, 2021

At the moment, the condition can only be managed using powerful corticosteroid drugs, which suppress the immune system but can have serious side effects if used long-term. Olumiant has also been in the spotlight for safety, and has warnings on its label for infections, malignancies and blood clots.

Labelling 107

Labelling Immunity Immunization 107

PharmaShots

MAY 11, 2023

Ariceum's expertise in radiochemistry & labeling technology will be useful to UCB in enhancing its capacity & discovery of highly distinctive products for immune-related diseases Ariceum will use a special library to screen against oncology targets of interest.

Immunization 40

Immunization Immunity Labelling 40

pharmaphorum

JUNE 11, 2021

takeover of Bioverativ in 2018, is designed to block the complement pathway of the immune response, which becomes activated in CAD. At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs. Sutimlimab, which Sanofi acquired via its $11.6

Immunity 96

Immunity Immunization Labelling 96

Express Pharma

FEBRUARY 21, 2024

There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). There’s a parallel BLA for DS-1062 in HR+ and HER2-breast cancer that is pending approval.

Chemotherapy 111

Chemotherapy Labelling Immunity Immunization 111

FDA Law Blog: Biosimilars

APRIL 30, 2023

Senate Committee on Health, Education, Labor and Pensions (“Senate HELP”) is scheduled to take up legislation that could significantly limit access to the courts and immunize critical FDA decisions from timely judicial review. Importantly, because FDA has sovereign immunity from damages claims, sponsors trapped in S. That bill is S.

Immunization 59

Immunization Immunity Biosimilars Labelling 59

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Ionis’ drug has however been held back by a limited label and some safety concerns and Ionis recently sold North American rights to the drug to Sobi.

Labelling 116

Labelling Immunity Immunization 116

LifeProNow

MARCH 28, 2023

Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that impacts approximately 14 million people in Europe. The results are particularly meaningful for dermatologists and patients who have been waiting for a more effective and convenient oral therapy to help manage this serious, chronic, immune-mediated disease.”

Adverse Reactions 130

Adverse Reactions Immunity Immunization Labelling 130

pharmaphorum

SEPTEMBER 16, 2022

. “Treating with Opdivo in earlier stages of cancer, when the immune system may be more responsive, has the potential to help prevent recurrence – a critical goal of improving patient outcomes,” she said in a statement.

Labelling 98

Labelling Immunity Immunization 98

pharmaphorum

DECEMBER 24, 2021

Biologic drugs used to treat plaque psoriasis are used off-label in GPP, but there’s little data on their effectiveness. In some cases the consequences are fatal, and at the moment there are no approved therapies in the US or Europe for GPP flares.

Labelling 103

Labelling Immunity Immunization 103

pharmaphorum

SEPTEMBER 18, 2020

But the findings of the latest phase 3 study, EMPACTA, could change that after Roche said it plans to share results with the FDA and other regulators to get its label expanded on the basis of the latest results. The study did not identify any new safety signals for Actemra/RoActemra.

Labelling 97

Labelling Immunity Immunization Hospitals 97

European Pharmaceutical Review

AUGUST 16, 2022

The RATIONALE 301 Phase III randomised, open-label study included more than 600 patients in the US, Europe and Asia. receptors on macrophages, helping the body’s immune cells to detect and fight tumours. The primary endpoint of non-inferiority of overall survival (OS) between the two groups of patients was met, BeiGene said.

Labelling 98

Labelling Immunity Immunization 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

Immunity 97

Immunity Immunization Vaccines Communication 97

Pharmaceutical Technology

APRIL 6, 2023

The PRIME scheme designation was granted by the EMA based on positive results obtained from the ongoing Phase IIb randomised, open-label KEYNOTE-942/mRNA-4157-P201 trial that enrolled 157 patients with stage III/IV melanoma. The Keytruda immunotherapy increases the body’s immune system ability to help identify and destroy tumour cells.

Vaccines 98

Vaccines Labelling Immunity Immunization 98

pharmaphorum

APRIL 30, 2021

BMS and bluebird had been hoping for a label allowing third-line use. “Despite advances in the treatment of multiple myeloma, there remains a high unmet need, especially for patients whose disease continues to progress,” said Peter Lebowitz, head of oncology R&D at Janssen.

Immunity 82

Immunity Immunization Labelling 82

pharmaphorum

SEPTEMBER 16, 2020

The phase 3 open-label trial will test the cocktail in patients hospitalised with COVID-19 and will compare the effects of adding the antibody cocktail REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

Hospitals 98

Hospitals Labelling Immunity Immunization 98

Pharmaceutical Business Review

OCTOBER 12, 2023

The multicentre, open-label study will evaluate the autologous fully human anti-cd19 chimeric antigen receptor (CAR) T cell therapy KYV-101 in adult scleroderma patients. Kyverna Therapeutics CEO Peter Maag said: “We are keen to initiate our KYSA-5 trial in this new patient population and generate data to support our KYV-101 design goals.

Immunity 52

Immunity Immunization Labelling 52

pharmaphorum

JANUARY 19, 2023

Alopecia areata is an autoimmune disease in which the immune system attacks the body’s hair follicles, causing hair to fall out, predominantly on the scalp, but also sometimes affecting other areas of the body like eyebrows, eyelashes, and facial hair. . The $11.50

Labelling 98

Labelling Immunity Immunization 98

The Thyroid Pharmacist

JUNE 30, 2023

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

Compounding 98

Compounding Immunity Immunization Compounding Pharmacies 98

Pharmaceutical Technology

OCTOBER 25, 2022

Based on positive data from the open-label, international, randomised, multicentre Phase III HIMALAYA clinical trial, the regulatory agency granted the approval. The dosage and schedule of the combination treatment is named the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).

Dosage 69

Dosage Labelling Immunity Immunization 69

Pharmaceutical Business Review

JULY 16, 2024

Kyverna CEO Peter Maag said: “We are eager to begin generating data from our sponsored trial to advance the knowledge on a potential immunological reset of the patient’s immune system. “We KYV-101 is advancing through clinical development with trials in two main areas of autoimmune disease: rheumatology and neurology.

Labelling 59

Labelling Immunity Immunization 59

LifeProNow

APRIL 19, 2023

This process may include undergoing therapies such as radiation or chemotherapy, both of which may weaken an individual’s immune system. Generally, before receiving this kind of transplant, the patient will undergo a course of treatments to remove their own stem cells and prepare the body for the new stem cells.

Adverse Reactions 130

Adverse Reactions Chemotherapy Labelling Immunity 130

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

European Pharmaceutical Review

MARCH 14, 2024

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

Diabetes 98

Diabetes Labelling Immunity Immunization 98

pharmaphorum

JUNE 7, 2021

Kymriah (tisagenlecleucel) was approved for relapsed/refractory ALL in 2017, but its label covers use in children and young adults aged up to 25, who account for the bulk of cases of the blood cancer. Around a quarter of patients treated with Tecartus had a severe immune reaction, and there were two deaths in the trial.

Labelling 105

Labelling Immunity Immunization 105

European Pharmaceutical Review

FEBRUARY 7, 2023

PVR blockade by NTX1088 is the first and only therapeutic approach aiming at restoring the antitumor immune activity of DNAM1 (CD226). The Phase I , open label clinical trial was initiated in November 2022. KEYTRUDA is MSD’s anti-PD1 therapy, in patients with locally advanced and metastatic solid tumours.

Immunity 52

Immunity Immunization Labelling 52

Pharmaceutical Technology

JUNE 15, 2023

Chugai Pharmaceutical has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for crovalimab to treat paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder in which parts of the immune system attack and damage red blood cells and platelets.

Labelling 52

Labelling Immunity Immunization 52

European Pharmaceutical Review

SEPTEMBER 15, 2022

At week 24, the open-label extension (Period 2) began, and all patients were treated with Skyrizi. New data from the open-label extension period revealed that at 100 weeks, 64 and 57 percent of patients initially treated with Skyrizi achieved ACR20 response in KEEPsAKE 1 and 2, respectively. The two studies are ongoing. .

Labelling 94

Labelling Immunity Immunization Hospitals 94

Pharmaceutical Technology

FEBRUARY 14, 2023

Cullinan Oncology has signed an exclusive licence with Harbour BioMed for clinical-stage B7H4 x 4-1BB bispecific immune activator HBM7008’s (CLN-418) development and marketing in the US. HBM7008 has been developed from HBICE, a next-generation heavy chain-only antibody (HCAb)-based multi-specific antibody discovery platform.

Immunity 52

Immunity Immunization Labelling 52

Pharma Packaging Solutions

JUNE 30, 2023

Whole blood, organ and tissue transplants, breast milk, antibodies for passive immunity, fecal microbiota, human reproductive cells, and stem-cell therapy are all examples of this type of biologic. We offer a variety of packaging services, including vial and ampule labeling, pharmaceutical kit assembly, and more.

Packaging 52

Packaging Immunity Immunization Vaccines 52

Pharmaceutical Technology

JUNE 16, 2023

The first-in-human, single-arm, open-label, dose-escalation and expansion trial aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of AVB-001 given intraperitoneally to people living with high-grade serous adenocarcinoma in the ovary, primary peritoneum or fallopian tube.

Immunity 52

Immunity Immunization Labelling 52

pharmaphorum

APRIL 5, 2022

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. GlobalData analyst Dr Sakis Palioras said in a recent research not that Kimmtrak’s 5.7 ” Image by Pexels from Pixabay .

Labelling 52

Labelling Chemotherapy Immunity Immunization 52

FADIC

MARCH 22, 2024

Fevers may also transpire after the administration of common childhood immunizations. Because antipyretics can also be found in many allergy, cold, cough, and flu products, patients should be advised to always read all medication labels prior to administration to avoid therapeutic duplications or possible medication overdose.

Immunity 100

Immunity Immunization Dosage Packaging 100

Safe Biologics

NOVEMBER 12, 2023

FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars- Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. ASBM surveys of U.S.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

The Thyroid Pharmacist

NOVEMBER 29, 2023

This is because I had learned about various adulterants found in supplements, how some supplement manufacturers don’t actually put the products that are on the label in the bottle, or that the dosages listed on the label may be completely different from what’s in the products. We have 290 expiring in April 2025.)

Health and Personal Care Stores 73

Health and Personal Care Stores Immunity Immunization Labelling 73

Pharmaceutical Technology

JULY 12, 2022

A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials. Health Canada has provided a target action date of 30 April next year.

Labelling 64

Labelling Immunity Immunization 64